NRC-2694 is under clinical development by Natco Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NRC-2694’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 23 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NRC-2694 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NRC-2694 overview

NRC-2694 is under development for the treatment of recurrent head and neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The drug is administered orally. It is a 6,7-dialkoxy quinazoline derivative, or salt derivative which possess anti-cancer activity. It acts by targeting the epidermal growth factor receptor (EGFR). It was also under development for advanced solid malignancies like non small cell lung cancer and HER-2 positive breast cancer.

Natco Pharma overview

Natco Pharma focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn’s disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Quick View NRC-2694 LOA Data

Report Segments
  • Innovator
Drug Name
  • NRC-2694
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.